Biosimilars Survey


The Gastrointestinal Society represents inflammatory bowel disease (IBD) patients on a variety of health care fronts, including access to medications. During the first part of 2015, we hosted a survey on our English ( & French ( websites to help understand IBD patients’ opinions and outlooks regarding biosimilars (subsequent entry biologics/SEBs). To qualify, survey participants had to confirm that they were either a person with IBD or a caregiver of a person with IBD. We had 423 respondents, 317 in English; 106 in French, but not everyone answered each question, as they were not mandatory. To view our results download the PDF of our full report or open the simplified poster version below.

Download a PDF of the results here.

View our poster version of the survey results.

SEB survey results poster image

Note: at the time of this publication, ‘subsequent entry biologics’ was the accepted nomenclature in Canada. However, the agreed upon term is now ‘biosimilars’.

We received funding from Janssen Inc. to conduct this independent survey.